Last Updated: 19 Sep 2024
Executive Summary
2Seventy Bio Inc. (TSVT) is a clinical-stage biopharmaceutical company focused on developing novel therapies for autoimmune and inflammatory diseases. Despite strong analyst support, the company faces challenges due to its negative earnings and low revenue. The stock price currently stands at $4.72, within its 52-week range.
Company Overview
2Seventy Bio is headquartered in Cambridge, Massachusetts, and has a market capitalization of approximately $243 million. The company's pipeline includes several promising drug candidates targeting various autoimmune diseases.
Fundamental Analysis
Revenue: TTM revenue of $44.12 million, showing a 0.751% decline year-over-year.
Earnings: TTM diluted EPS of -$3.06, indicating significant losses.
Profitability: Gross profit margin is negative, and operating margin is -2.27%.
Valuation: Price-to-sales ratio of 5.51, price-to-book ratio of 1.035, and EV-to-revenue ratio of 6.63.
Analyst Ratings: 2 strong buy, 3 hold, and 1 sell ratings.
Technical Analysis
Trend: Stock price is trending within its 52-week range.
Support and Resistance: Support at $4.531 (50-day moving average) and resistance at $4.72 (current price).
Indicators: Relative strength index (RSI) is neutral, indicating potential for both upside and downside movement.
Short Term Outlook
The stock price is facing resistance at the current level. If it breaks below the 50-day moving average, it could indicate further downside potential. However, if it manages to break above resistance, it could signal a potential rally.
Long Term Outlook
The company's pipeline has promising potential, but its negative earnings and low revenue are concerns. If 2Seventy Bio can successfully advance its drug candidates and improve its financial performance, it could have a positive impact on the stock price in the long term.
Analyst Recommendations
Analysts are generally cautious about 2Seventy Bio due to its financial struggles. However, some analysts see potential in the company's pipeline and believe it could be a long-term investment opportunity. It is important to note that analyst recommendations can change over time, and investors should always conduct their own due diligence before making any investment decisions.
